Provided by Tiger Fintech (Singapore) Pte. Ltd.

ADC Therapeutics SA

1.72
-0.0700-3.91%
Volume:213.90K
Turnover:365.76K
Market Cap:166.31M
PE:-0.74
High:1.78
Open:1.76
Low:1.67
Close:1.79
Loading ...

BRIEF-ADC Therapeutics Announces Positive Initial Data From Lotis-7 Clinical Trial Evaluating Zynlonta® In Combination With Bispecific

Reuters
·
11 Dec 2024

ADC Therapeutics announces data from LOTIS-7 Phase 1b open-label clinical trial

TIPRANKS
·
11 Dec 2024

ADC Therapeutics Announces Positive Initial Data From Lotis-7 Clinical Trial Evaluating Zynlonta® in Combination With Bispecific Antibody in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

THOMSON REUTERS
·
11 Dec 2024

ADC Therapeutics Sa - Zynlonta Plus Glofitamab Shows 94% Orr and 72% Cr Rate

THOMSON REUTERS
·
11 Dec 2024

ADC Therapeutics Sa - No Dose-Limiting Toxicities or High-Grade Crs/Icans Observed

THOMSON REUTERS
·
11 Dec 2024

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

PR Newswire
·
11 Dec 2024

ADC Therapeutics: Updated data from Phase 2 Zynlonta study published in Lancet

TIPRANKS
·
09 Dec 2024

ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma

PR Newswire
·
09 Dec 2024

BRIEF-ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial

Reuters
·
06 Dec 2024

ADC Therapeutics to Provide Initial Data Update on Lotis-7 Clinical Trial

THOMSON REUTERS
·
06 Dec 2024

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

PR Newswire
·
03 Dec 2024

BerGenBio ASA (FRA:7BG0) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Leadership ...

GuruFocus.com
·
14 Nov 2024

ADC Therapeutics Third Quarter 2024 Earnings: EPS Misses Expectations

Simply Wall St.
·
09 Nov 2024

ADC Therapeutics SA reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
09 Nov 2024

ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why

Benzinga
·
09 Nov 2024

Stephens Starts ADC Therapeutics With Overweight Rating, $6 Price Target

MT Newswires Live
·
08 Nov 2024